- Home
- IDR vs TIL Comparison
IDR vs TIL Comparison
Compare IDR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- TIL
- Stock Information
- Founded
- IDR 1996
- TIL 2018
- Country
- IDR United States
- TIL United States
- Employees
- IDR N/A
- TIL N/A
- Industry
- IDR Precious Metals
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- TIL Health Care
- Exchange
- IDR Nasdaq
- TIL Nasdaq
- Market Cap
- IDR 154.1M
- TIL 171.7M
- IPO Year
- IDR N/A
- TIL 2021
- Fundamental
- Price
- IDR $14.29
- TIL $13.23
- Analyst Decision
- IDR Strong Buy
- TIL Buy
- Analyst Count
- IDR 1
- TIL 5
- Target Price
- IDR $17.50
- TIL $114.00
- AVG Volume (30 Days)
- IDR 369.5K
- TIL 179.4K
- Earning Date
- IDR 05-08-2025
- TIL 05-20-2025
- Dividend Yield
- IDR N/A
- TIL N/A
- EPS Growth
- IDR 144.40
- TIL N/A
- EPS
- IDR 0.62
- TIL N/A
- Revenue
- IDR $27,144,971.00
- TIL N/A
- Revenue This Year
- IDR $9.76
- TIL N/A
- Revenue Next Year
- IDR N/A
- TIL N/A
- P/E Ratio
- IDR $23.37
- TIL N/A
- Revenue Growth
- IDR 67.42
- TIL N/A
- 52 Week Low
- IDR $8.50
- TIL $9.62
- 52 Week High
- IDR $19.75
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- IDR 41.73
- TIL 44.22
- Support Level
- IDR $14.91
- TIL $11.97
- Resistance Level
- IDR $17.00
- TIL $14.67
- Average True Range (ATR)
- IDR 1.07
- TIL 2.05
- MACD
- IDR -0.41
- TIL -0.04
- Stochastic Oscillator
- IDR 6.15
- TIL 17.87
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.